Treatment Trials

2 Clinical Trials for Various Conditions

Focus your search

      COMPLETED
      Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome
      Description

      This phase I/II trial studies the side effects of glutaminase inhibitor CB-839 in combination with azacitidine in treating patients with myelodysplastic syndrome that has spread to other places in the body. Glutaminase inhibitor CB-839 and azacitidine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

      Conditions
      Acute Myeloid Leukemia With Multilineage DysplasiaBlasts 20-30 Percent of Bone Marrow Nucleated CellsBlasts 20-30 Percent of Peripheral Blood White CellsChronic Myelomonocytic LeukemiaHigh Risk Myelodysplastic SyndromeIPSS Risk Category Intermediate-2Myelodysplastic Syndrome
      Talk to us
      TERMINATED
      Bosutinib in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase After Frontline TKI Failure
      Description

      This phase II trial studies how well bosutinib works in treating patients with chronic myeloid leukemia in chronic phase after frontline tyrosine kinase inhibitor (TKI) failure. Bosutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

      Conditions
      Blasts Under 15 Percent of Bone Marrow Nucleated CellsBlasts Under 15 Percent of Peripheral Blood White CellsBlasts Under 30 Percent of Bone Marrow Nucleated CellsBlasts Under 30 Percent of Peripheral Blood White CellsChronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
      Talk to us